Pall Corp

Pall — Q2 2013 Earnings Presentation

21 slides from Pall's earnings presentation, Mar 1, 2013

  1. Slide 1: Q2 FY 2013 Financial Results

    Better Lives. Better Planet.SM This presentation is the Confidential work product of Pall Corporation and no portion of this presentation may be copied, published, performed, or redistributed without the express written authority of a Pall corporate officer © 2012 Pall Corporation © 2013 Pall Corpor

  2. Slide 2: Forward-looking statements

    2 The matters discussed in this presentation contain “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. Results for the second quarter of fiscal year 2013 are preliminary until the Company's Form 10-Q is filed with the Securities and Exchange Commission

  3. Slide 3: Conference Call Replay Info

    3 Conference Call Replay Info  Toll-Free: 855.859.2056  International: 404.537.3406  Conference ID: 97942344  Internet: www.pall.com/investor

  4. Slide 4: Q2 Overview

    4 Q2 Overview  Life Sciences markets continue to perform well  Industrial end markets are still sluggish  Emerging Asia underperforming  Cost saving initiatives and productivity improvements progressing FY 2013 View Generally Unchanged All remarks in this presentation are on a “Continuing Operat

  5. Slide 5: Q2 Financial Summary

    5 $640 $662 $- $200 $400 $600 $800 Revenue % Growth Excluding FX FY 2012 FY 2013 Q2 Financial Summary Dollars in millions, except EPS data 17.0% 17.0% 10.0% 15.0% 20.0% Operating Profit Margin FY 2012 FY 2013 Q2 FY2012 0.67$ EBIT 0.02 Translational FX (0.01) Tax Rate & Sharecount 0.05 Q2 FY2013 0.73

  6. Slide 6: Q2 Sales by Segment

    6 Life Sciences Consumables $300 +11.7% Industrial Consumables $272 -5.9% Industrial Systems $61 +21.0% Life Sciences Systems $29 Flat 41% 45% 9% 5% Q2 Sales by Segment Dollars in millions Percentages outside pie charts and in box represent sales change excluding FX Percentages inside pie charts rep

  7. Slide 7: Q2 Life Sciences Consumables

    7 Q2 Life Sciences Consumables  BioPharmaceuticals +11% − Strength in biotech and impact of ForteBio®  Food and Beverage +5% – Geographic expansion  Medical +21% – Increased Pall-Aquasafe™ sales – Increased sales to OEMs Systems  Timing: Food & Beverage up; BioPharmaceuticals down Consumables 

  8. Slide 8: Q2 Life Sciences Segment Performance

    8 0% 30% 60% Gross Margin Segment Margin 58.4% -100 bps 25.1% -100 bps Q2 Life Sciences Segment Performance  Gross margin impacted by FX headwinds and unfavorable mix, partially offset by improved pricing  Segment margin impact of cost management offset by R&D investment

  9. Slide 9: Q2 Industrial Consumables

    9 Q2 Industrial Consumables  Process Technologies -12% − Weakness across end markets  Aerospace +14% − Commercial aviation strength  Microelectronics -6% − Continued end market weakness Systems  Strength in Process Technologies and Aerospace Consumables  Continued softness  Commercial Aerospac

  10. Slide 10: Q2 Industrial Segment Performance

    10 0% 30% 60% Gross Margin Segment Margin 45.0% -210 bps 14.4% +30 bps Q2 Industrial Segment Performance  Gross margin impacted by unfavorable mix and absorption  Segment margin improvement based upon cost management

  11. Slide 11: Q2 Regional

    11 $0 $100 $200 $300 Sales Orders Sales Orders Sales Orders $209 +11.9% $211 +1.4% $265 +1.9% $188 -1.2% Americas Europe Asia $282 +8.2% $185 -7.7% Q2 Regional Dollars in millions Sales and orders changes exclude FX Sales  Mature markets ~ +11%  Latin America ~ +28% Orders  Mature markets ~ +5% 

  12. Slide 12: Q2 Cash Flow and Working Capital

    12 Q2 Cash Flow and Working Capital YTD FY13 YTD FY12 Operating Cash Flow 89$ 204$ CapEx (42) (94) Free Cash Flow 47$ 110$ Other Significant Sources/(Uses) of Cash: Pr ceeds from sale of assets 542$ 20$ Acquisition of businesses - (26) Dividends (53) (40) Borrowing/Repayment under Financing Faciliti

  13. Slide 13: Conclusion: Closing Remarks, Q&A

    13 Conclusion  Closing Remarks  Q&A

  14. Slide 14: Appendix

    Better Lives. Better Planet.SM This presentation is the Confidential work product of Pall Corporation and no portion of this presentation may be copied, published, performed, or redistributed without the express written authority of a Pall corporate officer © 2012 Pall Corporation © 2013 Pall Corpor

  15. Slide 15: Q2 Earnings and FY 2013 Estimates from Continuing Operations

    15 Appendix: Q2 Earnings and FY 2013 Estimates from Continuing Operations Reconciliation of Non-GAAP Financial Measures Diluted EPS from continuing operations as reported 0.70$ 0.63$ 3.12$ Discrete Items: ROTC after pro forma tax effect 0.03 0.04 0.06 Tax Adjustments - - (0.09) Interest Adjustments

  16. Slide 16: Q2 Life Sciences Sales By Market & Technology

    16 Appendix: Q2 Life Sciences Sales By Market & Technology Reconciliation of Non-GAAP Financial Measures Q2FY13 Q2 FY13 Estimated Impact of FX Q2 FY13 Estimate Excluding FX Q2FY12 % Change Excluding FX Consumables Sales: BioPharmaceuticals 201,658$ (1,071)$ 202,729$ 182,518$ 11.1% Food & Beverage 45

  17. Slide 17: Q2 Industrial Sales By Market & Technology

    17 Appendix: Q2 Industrial Sales By Market & Technology Reconciliation of Non-GAAP Financial Measures Q2 FY13 Q2 FY13 Estimated Impact of FX Q2 FY13 Estimate Excluding FX Q2 FY12 % Change Excluding FX Consumables Sales: Process Technologies 143,146$ (899)$ 144,045$ 164,010$ -12.2% Aerospace 60,578 1

  18. Slide 18: Q2 Sales by Segment and Region

    18 Appendix: Q2 Sales by Segment and Region Reconciliation of Non-GAAP Financial Measures Q2 FY13 Q2 FY13 Estimated Impact of FX Q2 FY13 Estimate Excluding FX Q2 FY12 % Change Excluding FX Life Sciences Sales: Americas 104,018$ (789)$ 104,807$ 84,014$ 24.8% Europe 159,360 603 158,757 152,027 4.4% As

  19. Slide 19: Q2 Orders by Technology

    19 Appendix: Q2 Orders by Technology Reconciliation of Non-GAAP Financial Measures Dollars in thousands Q2 FY13 Q2 FY13 Estimated Impact of FX Q2 FY13 Estimate Excluding FX Q2 FY12 % Change Excluding FX Life Sciences Orders: Consumables 322,731$ (2,110)$ 324,841$ 285,748$ 13.7% Systems 28,603 175 28

  20. Slide 20: Q2 Operating Profit

    20 Appendix: Q2 Operating Profit Reconciliation of Non-GAAP Financial Measures Operating Profit Q2 FY13 Q2 FY12 Life Sciences segment profit 82,477$ 78,088$ Industrial segment profit 48,104 48,129 Total segment profit 130,581$ 126,217$ General corporate expenses (18,026) (17,678) Operating profit 11

  21. Slide 21: Better Lives. Better Planet.

    Better Lives. Better Planet.SM This presentation is the Confidential work product of Pall Corporation and no portion of this presentation may be copied, published, performed, or redistributed without the express written authority of a Pall corporate officer © 2012 Pall Corporation © 2013 Pall Corpor

Pall — Q2 2013 Earnings Presentation on 6ix